Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 10, 2015, Pages 1136-1142

  Krop, Ian E ^a   Suter, Thomas M ^b   Dang, Chau T ^c   Dirix, Luc ^e   Romieu, Gilles ^f   Zamagni, Claudio ^h   Citron, Marc L ^d   Campone, Mario ^g   Xu, Na ^j   Smitt, Melanie ^j   Gianni, Luca ⁱ  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e SINT AUGUSTINUS HOSPITAL   (Belgium)

^f CENTRE VAL D AURELLE   (France)

^g Institut de Cancérologie de l'Ouest/René Gauducheau ^*  (France)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; EMTANSINE; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; EPISTAXIS; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; LIVER TOXICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RASH; SIDE EFFECT; SUPRAVENTRICULAR PREMATURE BEAT; THROMBOCYTOPENIA; TRICUSPID VALVE DISEASE; VERTIGO; VOMITING; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; HEART FAILURE; METABOLISM; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FLUOROURACIL; HEADACHE; HEART FAILURE; HUMANS; MAYTANSINE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; RECEPTOR, ERBB-2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927627880     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.7782     Document Type: Conference Paper

References (30)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Ross JS, Slodkowska EA, Symmans WF, et al: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368, 2009
3. Pathmanathan N, Provan PJ, Mahajan H, et al: Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. Breast 21:724-729, 2012
4. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
5. Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastases after newly diagnosed breast cancer. J Clin Oncol 24:5658-5663, 2006
6. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
8. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
9. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
10. Halyard MY, Pisansky TM, Dueck AC, et al: Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 27:2638-2644, 2009
11. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
12. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280-9290, 2008
13. Erickson HK, Park PU, Widdison WC, et al: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433, 2006
14. Junttila TT, Li G, Parsons K, et al: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356, 2011
15. Hurvitz SA, Dirix L, Kocsis J, et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157-1163, 2013
16. Diéras V, Harbeck N, Budd GT, et al: Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: An integrated safety analysis. J Clin Oncol 32:2750-2757, 2014
17. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
18. Krop IE, Kim SB, González Martín A, et al: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial. Lancet Oncol 15:689-699, 2014
19. Kadcyla prescribing information. South San Francisco, CA, Genentech, 2013
20. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
21. Procter M, Suter TM, de Azambuja E, et al: Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428, 2010
22. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
23. Perez EA, Romond EH, Suman VJ, et al: Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
24. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
25. US Department of Health and Human Services: Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. http://www.fda.gov/ downloads/Drugs/../Guidances/UCM174090.pdf
26. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007
27. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
28. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An openlabel, randomised controlled trial. Lancet 382:1021-1028, 2013
29. Morris PG, Iyengar NM, Patil S, et al: Longterm cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 119:3943-3951, 2013
30. Gupta M, Wang B, Carrothers TJ, et al: Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Pharmacol Drug Dev 2:11-24, 2013